Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01131013 · ClinicalTrials.gov registry record · Phase 2
A Study of CK-2017357 in Patients With Peripheral Artery Disease and Symptomatic Claudication
A Phase 2 study, sponsored by Cytokinetics.
- Completed
- Registry status
- Phase 2
- Development phase
- 61
- Enrollment target
NCT01131013: Completed Phase 2 study, sponsored by Cytokinetics.
NCT01131013 is a Phase 2 study that has completed, run by Cytokinetics. The registered enrollment target is 61 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (54% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01131013, a Phase 2 study, has completed, sponsored by Cytokinetics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 61 participants
- Enrollment target
Study Summary
The primary objective of this early-stage clinical study is to demonstrate an effect of single doses of CK-2017357 on measures of skeletal muscle function and fatigability in patients with peripheral artery disease and symptomatic claudication.
Primary Outcome
Heel raises will be monitored by an electrogoniometer placed on the index leg and performed once every other second until onset of claudication pain or fatigue as determined by electrogoniometry
Interventions
- DRUG Placebo
- DRUG 375 mg CK-2017357
- DRUG 500 mg CK-2017357
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2010-05 |
| Est. Completion | 2011-03 |
| Phase | Phase 2 |
What the finished NCT01131013 record still lists
NCT01131013 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 61 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (54% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01131013 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01131013 about?
NCT01131013 is a clinical study titled "A Study of CK-2017357 in Patients With Peripheral Artery Disease and Symptomatic Claudication". The primary objective of this early-stage clinical study is to demonstrate an effect of single doses of CK-2017357 on measures of skeletal muscle function and fatigability in patients with peripheral artery disease and symptomatic claudication.
What is the current status of trial NCT01131013?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 61 participants. The study started on 2010-05. Estimated completion is 2011-03.
What interventions are being tested in trial NCT01131013?
The interventions under investigation include: Placebo (DRUG), 375 mg CK-2017357 (DRUG), 500 mg CK-2017357 (DRUG).
Who is sponsoring clinical trial NCT01131013?
This trial is sponsored by Cytokinetics, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01131013's enrollment target sits among peer trials
61 1026th of 2000 higher than 974 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04115306 · 61 participants · Phase 1
Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer
- NCT05070845 · 61 participants · Phase 2
Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia
- NCT05187832 · 61 participants · Phase 1
A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer
- NCT05269316 · 61 participants · Phase 1
Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia